PUBLISHER: Meticulous Research | PRODUCT CODE: 2138406
PUBLISHER: Meticulous Research | PRODUCT CODE: 2138406
Pharmacogenomics Market Size, Share, and Industry Analysis by Offering, Technology, Application, End User, and Geography - Global Forecast to 2036
The global Pharmacogenomics Market was valued at USD 11,680.0 million in 2025 and is estimated to reach USD 12,720.5 million in 2026. The market is projected to reach USD 29,866.9 million by 2036, registering a CAGR of 8.9% during the forecast period (2026-2036). This report provides a comprehensive assessment of the expanding pharmacogenomics market by examining genetic testing, drug-gene interactions, pharmacogenomic labeling, preemptive panel testing, clinical decision support, therapeutic applications, competitive developments, and future growth opportunities across precision medicine and clinical diagnostics.
Pharmacogenomics comprises the consumables, instruments, software, and services used to evaluate how genetic variation affects a patient's response to medicines, with the aim of improving treatment efficacy and avoiding adverse drug reactions. The market includes PCR-based genotyping assays, sequencing panels and genomes, microarrays, mass spectrometry, electrophoresis, interpretation software, and clinical decision support solutions used across oncology, mental health, infectious diseases, cardiology, neurological disorders, pain management, and other therapeutic areas. The market ecosystem extends from instrument and reagent manufacturers to hospital and reference laboratories, interpretation software providers, pharmaceutical companies, healthcare systems, and prescribers who act on test results.
The growth of this market is mainly driven by the growing number of drugs with pharmacogenomic labeling, growing clinical evidence for preemptive panel testing, the rising geriatric population and polypharmacy, and increasing regulatory focus on pharmacogenomic drug safety. In addition, the integration of pharmacogenomic results into electronic health records, the move by national health systems toward panel-based testing, and expanding pharmacogenomic applications in oncology are further supporting market growth. The growing adoption of genotype-guided prescribing and the increasing availability of sequencing-based methods for complex pharmacogenes are also creating new opportunities.
Pharmacogenomic testing is moving from reactive, single-gene testing toward preemptive panels whose results can be stored in electronic health records and reused whenever an affected medicine is prescribed. The FDA Table of Pharmacogenomic Biomarkers in Drug Labeling covers more than 260 drugs and over 360 drug-biomarker pairs, while clinical studies such as PREPARE and PRIME Care have strengthened the evidence supporting genotype-guided care. This report evaluates the impact of clinical guidelines, regulatory requirements, reimbursement, clinician awareness, electronic health record integration, test costs, and pharmaceutical partnerships on the market's future development.
This report delivers an in-depth analysis of the market by evaluating offerings, technologies, applications, end users, clinical adoption trends, drug-labeling requirements, payer coverage, testing workflows, clinical decision support, and competitive strategies shaping industry growth. It assesses how targeted PCR genotyping, sequencing, long-read methods, microarrays, mass spectrometry, artificial intelligence-assisted interpretation, point-of-care testing, and structured electronic health record integration are improving pharmacogenomic testing, result interpretation, and prescribing decisions. The study also provides strategic market forecasts, segment-level insights, and regional analysis to support informed business, investment, product development, and market-entry decisions.
Market Dynamics
The growing number of drugs with pharmacogenomic labeling remains one of the primary drivers of the pharmacogenomics market. The FDA Table of Pharmacogenomic Biomarkers in Drug Labeling covers more than 260 drugs and over 360 drug-biomarker pairs, and cancer therapies account for a substantial share of biomarker-drug pairs for which testing is required. Regulatory guidance for genes such as CYP2C19, HLA-B57:01, HLA-B15:02, TPMT, NUDT15, UGT1A1, and DPYD is creating defined demand for tests when medicines with clinically relevant gene-drug interactions are prescribed.
Clinical evidence for preemptive pharmacogenomic testing is further accelerating market adoption. The PREPARE study demonstrated that a 12-gene panel reduced clinically relevant adverse drug reactions by 30% across 6,944 patients in seven European countries. The PRIME Care trial also found that genotype-guided care reduced prescriptions with substantial drug-gene interactions from 20% to 11%. These findings are supporting the transition from reactive single-gene testing toward preemptive panels that can provide actionable information throughout a patient's treatment journey.
The rising geriatric population and increasing prevalence of polypharmacy are creating additional demand. Older adults take more medicines for longer periods and are more vulnerable to adverse drug reactions because of age-related changes in drug metabolism and clearance. The growing burden of cardiovascular disease, cancer, depression, neurological disorders, and chronic pain increases the number of prescribing decisions that may be influenced by pharmacogenomic variation. As the global population ages, the potential value of preemptive testing is expected to increase.
Publicly funded healthcare systems are gradually integrating pharmacogenomics into routine care. National health services and clinical guidelines include testing before fluoropyrimidine chemotherapy, thiopurine treatment, clopidogrel therapy, and other medicines with established drug-gene interactions. The European Medicines Agency and national agencies have strengthened recommendations for pre-treatment testing, while Medicare coverage through the MolDX program is supporting testing where clinical guidance or FDA labeling establishes medical value.
The integration of pharmacogenomic information into electronic health records is creating significant opportunities for software and services. A test delivers value only when its result reaches the prescriber at the point of prescribing, sometimes years after the original test was performed. Structured result storage, clinical decision support, automated alerts, genotype-to-prescription interpretation, and dosing guidance are therefore becoming essential components of pharmacogenomic workflows. These requirements are shifting a larger share of value toward interpretation software, data platforms, and integration services.
Sequencing-based testing is expanding as a faster-growing alternative to targeted genotyping. PCR remains the most widely used method because of its low cost and speed for known variants, but sequencing can resolve complex genes such as CYP2D6 and detect rare variants that targeted assays may miss. Panel sequencing, long-read sequencing, artificial intelligence-assisted interpretation, and point-of-care genotyping are broadening access and improving the ability to characterize pharmacogenes comprehensively.
Despite favorable market conditions, uneven reimbursement remains an important restraint. Payers increasingly require randomized evidence of improved outcomes, while coverage varies by indication, payer, and geography. Commercial reimbursement moved in opposite directions in 2025, as some programs expanded coverage while UnitedHealthcare withdrew coverage of multi-gene panels. Patients and providers may therefore face uncertainty regarding payment, limiting adoption even when guidelines and clinical evidence support testing.
Limited clinician awareness and implementation challenges also constrain market growth. Many prescribers receive little training in pharmacogenomics, are uncertain how to act on results, or work in systems that do not present results at the point of prescribing. A test may be available and clinically validated but remain underused if healthcare providers lack genetic counseling support, electronic health record integration, or clear recommendations for changing therapy.
The cost of multi-gene panels and sequencing-based tests can further limit access. Targeted tests may be relatively inexpensive, while comprehensive panels require additional sequencing, bioinformatics, interpretation, and reporting. Laboratories and payers also face challenges in evaluating the clinical utility of tests across multiple therapeutic areas. In addition, intellectual property, regulatory requirements, data privacy, and the need to maintain continuously updated prescribing guidance can increase operating costs.
The market nevertheless presents substantial opportunities through preemptive pharmacogenomic panels, oncology germline testing, sequencing and long-read methods, integrated clinical decision support, point-of-care genotyping, evidence generation for payer coverage, and testing expansion in Asia-Pacific. Companies that combine broad pharmacogene content, reliable interpretation, strong clinical evidence, structured electronic health record integration, and reimbursement support are expected to be well positioned to benefit from market growth.
Segment Analysis
The report provides detailed market analysis across offering, technology, application, end user, and geography, enabling stakeholders to identify high-growth opportunities and evolving trends in precision medicine, drug safety, clinical genotyping, pharmacogenomic panels, oncology testing, and clinical decision support.
Based on offering, the market is segmented into Consumables, Instruments, and Software & Services. Consumables are expected to account for the largest share of 71.5% of the global Pharmacogenomics Market in 2026 and are projected to register the highest CAGR of 9.1% during the forecast period. The large share of this segment is mainly due to the recurring use of reagents, kits, assay components, and consumable materials in every pharmacogenomic test run. As testing volumes increase across the installed instrument base, demand for consumables is expected to expand. Software & Services are also gaining importance as interpretation, clinical decision support, electronic health record integration, and data management become essential to the clinical use of pharmacogenomic results.
Based on technology, the market is segmented into Polymerase Chain Reaction, Sequencing, Microarray, Mass Spectrometry, Electrophoresis, and Other Technologies. PCR is expected to account for the largest share of 39.5% of the pharmacogenomics market in 2026 because of the low cost, speed, and established use of targeted genotyping for known variants. However, Sequencing is projected to register the highest CAGR of 11.4% during the forecast period, as panel sequencing and long-read methods resolve complex pharmacogenes such as CYP2D6, identify rare variants, and support broader preemptive testing. Artificial intelligence-assisted interpretation and point-of-care genotyping are expected to further expand the role of sequencing and molecular testing.
Based on application, the market is segmented into Oncology, Mental Health, Infectious Diseases, Cardiology, Neurological Disorders, Pain Management, and Other Applications. Oncology is expected to account for the largest share of 36.0% of the pharmacogenomics market in 2026 and is projected to register the highest CAGR of 10.6% during the forecast period. The large share of this segment is attributed to the concentration of pharmacogenomic labeling in cancer therapies, which account for 75.5% of biomarker-drug pairs for which testing is required. Oncology pharmacogenomics includes testing for chemotherapy toxicity, thiopurine response, irinotecan metabolism, and targeted treatment selection, creating sustained demand for testing and interpretation services.
Based on end user, the market is segmented into Hospitals & Diagnostic Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, and Other End Users. Hospitals & Diagnostic Laboratories are expected to account for the largest share of 62.9% of the pharmacogenomics market in 2026 and are projected to register the highest CAGR of 10.2% during the forecast period. The large share of this segment is due to the concentration of clinical genotyping in hospital and reference laboratories, as well as coverage under programs such as Medicare MolDX. Academic and research institutes continue to support clinical evidence generation, while pharmaceutical and biotechnology companies use pharmacogenomics in drug development, clinical trials, biomarker discovery, and companion diagnostic strategies.
Regional Analysis
The report provides comprehensive market analysis across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. Regional evaluations consider pharmacogenomic labeling, clinical guidelines, reimbursement, healthcare infrastructure, testing capacity, population genetics, electronic health record integration, drug development, clinician awareness, and investments influencing market growth.
North America is expected to account for the largest share of 41.4% of the global Pharmacogenomics Market in 2026. The region leads because testing is both covered and required in several clinically established gene-drug pairs. Medicare covers testing where CPIC guidance or FDA labeling supports the gene-drug relationship, while regulatory actions have strengthened DPYD testing before fluoropyrimidine chemotherapy. The U.S. is expected to account for the largest share of the regional market. However, commercial reimbursement remains uneven, as UnitedHealthcare stopped covering multi-gene panels while new testing services and laboratory entrants continue to expand market availability.
Europe is expected to account for the second-largest share of 31.0% of the pharmacogenomics market in 2026. The region has generated strong clinical evidence for preemptive testing, including the PREPARE study across seven European countries. European regulators acted early on DPD deficiency, and clear guidelines, public health system adoption, and reimbursement are supporting the use of pharmacogenomics. National healthcare services are integrating testing into oncology, cardiovascular, and other clinical pathways. Germany is expected to account for the largest share of the European market.
Asia-Pacific is projected to register the highest CAGR of 10.1% during the forecast period. Population genetics increase the clinical value of pharmacogenomic testing in the region, where loss-of-function alleles and drug toxicity-associated variants can occur at higher frequencies among some Asian populations. China, Japan, and India together account for 84.3% of the regional market in 2026. China is projected to register the highest CAGR of any country, at 11.3%, supported by expanding healthcare infrastructure, genomic medicine initiatives, pharmaceutical activity, and increasing adoption of clinical testing.
Latin America is expected to account for a share of 4.7% of the pharmacogenomics market in 2026. Testing depends largely on private laboratories and out-of-pocket payment, while public health systems have not yet established routine pharmacogenomic pathways across the region. Growth is expected to follow the expansion of private laboratory networks, clinical testing capacity, and precision medicine initiatives. Brazil is expected to account for the largest share of the regional market, at 59.3%, in 2026.
The Middle East & Africa is expected to account for a share of 2.5% of the pharmacogenomics market in 2026. Gulf states are building population genome resources and expanding precision medicine programs, while laboratory capacity and specialist access limit testing across much of Sub-Saharan Africa. Growth is expected to concentrate in the Gulf, where national genome projects, high rates of consanguinity, and investments in genomic healthcare are creating demand for pharmacogenomic testing. Saudi Arabia is expected to account for a share of 33.2% of the regional market in 2026.
Competitive Landscape
The report presents a comprehensive evaluation of the competitive environment by examining the strategic positioning of leading market participants, their pharmacogenomic assay portfolios, PCR and sequencing platforms, microarray and mass spectrometry technologies, interpretation software, clinical decision support systems, testing services, regulatory status, clinical evidence, reimbursement initiatives, product launches, acquisitions, partnerships, geographic expansion programs, research and development investments, and recent business developments.
Competitive benchmarking enables stakeholders to evaluate companies based on pharmacogene content, test menu breadth, installed base, cost per test, turnaround time, variant detection capability, interpretation quality, clinical decision support, electronic health record integration, regulatory compliance, clinical evidence, payer coverage, laboratory capacity, and pricing. The study also analyzes how companies are responding to the shift from reactive single-gene tests to preemptive panels, the growth of sequencing and long-read methods, the expansion of oncology testing, and uncertainty in commercial reimbursement.
The global Pharmacogenomics Market combines instrument and reagent manufacturers, sequencing and array platform suppliers, interpretation software providers, clinical testing laboratories, and pharmaceutical companies. Approvals and product launches accounted for more than half of the strategic activity of leading companies between January 2025 and September 2026. Acquisitions and investments are expanding capabilities in oncology, sequencing, clinical interpretation, and data platforms. Key companies profiled in the report include F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Illumina, Inc., Danaher Corporation, Agilent Technologies, Inc., QIAGEN N.V., Abbott Laboratories, Bio-Rad Laboratories, Inc., Revvity, Inc., Pacific Biosciences of California, Inc., and Myriad Genetics, Inc.
How This Report Helps
Provides accurate market size estimates and long-term forecasts for the global pharmacogenomics market.
Evaluates the impact of pharmacogenomic drug labeling, clinical guidelines, preemptive testing, polypharmacy, regulatory action, and reimbursement on market growth.
Identifies high-growth opportunities across offerings, technologies, applications, end users, and geographic regions.
Analyzes emerging trends in pharmacogenomic panels, sequencing, long-read methods, artificial intelligence-assisted interpretation, point-of-care testing, and electronic health record integration.
Assesses the influence of clinician awareness, test costs, payer coverage, clinical evidence, data privacy, regulatory requirements, and implementation capacity on adoption.
Benchmarks leading companies based on test menus, assay technologies, interpretation capabilities, clinical decision support, installed base, evidence generation, reimbursement access, partnerships, and competitive positioning.
Supports product development, clinical testing strategy, investment planning, partnership evaluation, reimbursement strategy, market entry, laboratory expansion, and business growth decisions.
Delivers actionable market intelligence for diagnostic laboratories, hospitals, pharmaceutical and biotechnology companies, sequencing and assay providers, academic researchers, clinicians, payers, investors, distributors, and healthcare organizations.
Key Questions Answered
What is the current size of the global pharmacogenomics market, and how is it expected to evolve through 2036?
Which technological, clinical, regulatory, reimbursement, and economic factors are driving market growth?
What are the major drivers, restraints, opportunities, and challenges influencing industry development?
Which offering, technology, application, end-user, and regional segments are expected to experience the strongest growth?
Why are Consumables expected to account for the largest offering share, and why are they projected to register the highest CAGR?
How will sequencing, long-read methods, PCR genotyping, and artificial intelligence-assisted interpretation influence market development?
Why is Oncology expected to dominate the application segment and register the fastest growth?
How are pharmacogenomic labeling, preemptive panel testing, clinical guidelines, and electronic health record integration changing prescribing decisions?
What role do reimbursement, payer evidence, clinician awareness, and point-of-prescribing decision support play in market adoption?
Which geographic markets present the most attractive business opportunities for pharmacogenomics companies?
Who are the leading companies operating in the market, and what competitive strategies are they adopting?
What recent product launches, acquisitions, partnerships, regulatory actions, clinical studies, and technological innovations are shaping the competitive landscape?
How can stakeholders leverage market intelligence from this report to support investment decisions, product development, laboratory planning, reimbursement strategy, competitive benchmarking, and long-term business strategy?
TABLE OF CONTENTS
1. Introduction
- 1.1. Market Definition & Scope
- 1.2. Market Ecosystem
- 1.3. Currency & Limitations
- 1.4. Key Stakeholders
2. Research Methodology
- 2.1. Research Approach
- 2.2. Data Collection & Validation
- 2.2.1. Secondary Research
- 2.2.2. Primary Research
- 2.3. Market Assessment
- 2.3.1. Market Size Estimation
- 2.3.2. Bottom-Up Approach
- 2.3.3. Top-Down Approach
- 2.3.4. Growth Forecast
- 2.4. Assumptions for the Study
3. Executive Summary
4. Market Insights
- 4.1. Overview
- 4.2. Factors Affecting Market Growth
- 4.2.1. Drivers
- 4.2.1.1. Growing Number of Drugs with Pharmacogenomic Labeling Supporting Market Growth
- 4.2.1.2. Growing Clinical Evidence for Preemptive Panel Testing Driving Adoption
- 4.2.1.3. Rising Geriatric Population and Polypharmacy Boosting Demand for Testing
- 4.2.1.4. Increasing Regulatory Focus on Pharmacogenomic Drug Safety
- 4.2.2. Restraint
- 4.2.2.1. High Cost of Testing and Inconsistent Payer Coverage Restraining Adoption
- 4.2.3. Opportunities
- 4.2.3.1. Integration of Pharmacogenomics into Electronic Health Records Creating Opportunities for Software and Service Providers
- 4.2.3.2. National Health Systems Moving Toward Panel-Based Testing Generating Opportunities
- 4.2.3.3. Growing Awareness Regarding Adverse Drug Reactions Generating Opportunities for Market Players
- 4.2.3.4. Expanding Pharmacogenomic Applications in Oncology Generating Opportunities
- 4.2.4. Challenges
- 4.2.4.1. Low Clinician Awareness and Implementation Gaps Remaining a Major Challenge
- 4.2.4.2. Mixed Clinical-Trial Evidence and Payer Evidence Requirements Impacting Market Growth
- 4.2.1. Drivers
- 4.3. Key Trends
- 4.3.1. Shift from Targeted Genotyping Toward Sequencing-Based Testing
- 4.3.2. Artificial Intelligence in Pharmacogenomics
- 4.3.3. Point-of-Care Genotyping
- 4.3.4. Pharmacy-Based and Direct-to-Consumer Testing
- 4.4. Regulatory Analysis
- 4.4.1. North America
- 4.4.2. Europe
- 4.4.3. Asia-Pacific
- 4.4.4. Latin America
- 4.4.5. Middle East & Africa
- 4.5. Reimbursement Analysis
- 4.6. Pricing Analysis
- 4.7. Porter's Five Forces Analysis
- 4.7.1. Bargaining Power of Buyers
- 4.7.2. Bargaining Power of Suppliers
- 4.7.3. Threat of Substitutes
- 4.7.4. Threat of New Entrants
- 4.7.5. Degree of Competition
- 4.8. Value Chain Analysis
- 4.8.1. Research & Development
- 4.8.2. Raw Material & Component Supply
- 4.8.3. Manufacturing
- 4.8.4. Distribution
- 4.8.5. Testing & Interpretation
- 4.8.6. End Use
5. Pharmacogenomics Market Assessment, by Offering
- 5.1. Overview
- 5.2. Consumables
- 5.3. Instruments
- 5.4. Software & Services
6. Pharmacogenomics Market Assessment, by Technology
- 6.1. Overview
- 6.2. Polymerase Chain Reaction (PCR)
- 6.3. Sequencing
- 6.4. Microarray
- 6.5. Mass Spectrometry
- 6.6. Electrophoresis
- 6.7. Other Technologies
7. Pharmacogenomics Market Assessment, by Application
- 7.1. Overview
- 7.2. Oncology
- 7.3. Mental Health
- 7.4. Infectious Diseases
- 7.5. Cardiology
- 7.6. Neurological Disorders
- 7.7. Pain Management
- 7.8. Other Applications
8. Pharmacogenomics Market Assessment, by End User
- 8.1. Overview
- 8.2. Hospitals & Diagnostic Laboratories
- 8.3. Academic & Research Institutes
- 8.4. Pharmaceutical & Biotechnology Companies
- 8.5. Other End Users
9. Pharmacogenomics Market Assessment, by Geography
- 9.1. Overview
- 9.2. North America
- 9.2.1. U.S.
- 9.2.2. Canada
- 9.3. Europe
- 9.3.1. Germany
- 9.3.2. France
- 9.3.3. U.K.
- 9.3.4. Italy
- 9.3.5. Spain
- 9.3.6. Rest of Europe
- 9.4. Asia-Pacific
- 9.4.1. China
- 9.4.2. Japan
- 9.4.3. India
- 9.4.4. South Korea
- 9.4.5. Australia
- 9.4.6. Rest of Asia-Pacific
- 9.5. Latin America
- 9.5.1. Brazil
- 9.5.2. Mexico
- 9.5.3. Rest of Latin America
- 9.6. Middle East & Africa
- 9.6.1. Saudi Arabia
- 9.6.2. UAE
- 9.6.3. Rest of Middle East & Africa
10. Competitive Landscape
- 10.1. Overview
- 10.2. Key Growth Strategies
- 10.3. Competitive Benchmarking
- 10.4. Competitive Dashboard
- 10.4.1. Industry Leaders
- 10.4.2. Market Differentiators
- 10.4.3. Vanguards
- 10.5. Market Ranking, 2025
11. Company Profiles
- 11.1. F. Hoffmann-La Roche Ltd (Switzerland)
- 11.1.1. Company Overview
- 11.1.2. Financial Overview
- 11.1.3. Product Portfolio
- 11.1.4. Strategic Developments
- 11.1.5. SWOT Analysis
- 11.2. Thermo Fisher Scientific Inc. (U.S.)
- 11.2.1. Company Overview
- 11.2.2. Financial Overview
- 11.2.3. Product Portfolio
- 11.2.4. Strategic Developments
- 11.2.5. SWOT Analysis
- 11.3. Illumina, Inc. (U.S.)
- 11.3.1. Company Overview
- 11.3.2. Financial Overview
- 11.3.3. Product Portfolio
- 11.3.4. Strategic Developments
- 11.3.5. SWOT Analysis
- 11.4. Danaher Corporation (U.S.)
- 11.4.1. Company Overview
- 11.4.2. Financial Overview
- 11.4.3. Product Portfolio
- 11.4.4. Strategic Developments
- 11.4.5. SWOT Analysis
- 11.5. Agilent Technologies, Inc. (U.S.)
- 11.5.1. Company Overview
- 11.5.2. Financial Overview
- 11.5.3. Product Portfolio
- 11.5.4. Strategic Developments
- 11.5.5. SWOT Analysis
- 11.6. QIAGEN N.V. (Netherlands)
- 11.6.1. Company Overview
- 11.6.2. Financial Overview
- 11.6.3. Product Portfolio
- 11.6.4. Strategic Developments
- 11.6.5. SWOT Analysis
- 11.7. Abbott Laboratories (U.S.)
- 11.7.1. Company Overview
- 11.7.2. Financial Overview
- 11.7.3. Product Portfolio
- 11.7.4. Strategic Developments
- 11.7.5. SWOT Analysis
- 11.8. Bio-Rad Laboratories, Inc. (U.S.)
- 11.8.1. Company Overview
- 11.8.2. Financial Overview
- 11.8.3. Product Portfolio
- 11.8.4. Strategic Developments
- 11.8.5. SWOT Analysis
- 11.9. Revvity, Inc. (U.S.)
- 11.9.1. Company Overview
- 11.9.2. Financial Overview
- 11.9.3. Product Portfolio
- 11.9.4. Strategic Developments
- 11.9.5. SWOT Analysis
- 11.10. Pacific Biosciences of California, Inc. (U.S.)
- 11.10.1. Company Overview
- 11.10.2. Financial Overview
- 11.10.3. Product Portfolio
- 11.10.4. Strategic Developments
- 11.11. Myriad Genetics, Inc. (U.S.)
- 11.11.1. Company Overview
- 11.11.2. Financial Overview
- 11.11.3. Product Portfolio
- 11.11.4. Strategic Developments
- 11.11.5. SWOT Analysis
12. Appendix
- 12.1. Available Customization
- 12.2. Related Reports
LIST OF TABLES
List of Tables
- Table 1 Key Secondary Sources
- Table 2 Global Pharmacogenomics Market, by Offering, 2024-2036 (USD Million)
- Table 3 Global Pharmacogenomics Market for Consumables, by Country/Region, 2024-2036 (USD Million)
- Table 4 Global Pharmacogenomics Market for Instruments, by Country/Region, 2024-2036 (USD Million)
- Table 5 Global Pharmacogenomics Market for Software & Services, by Country/Region, 2024-2036 (USD Million)
- Table 6 Global Pharmacogenomics Market, by Technology, 2024-2036 (USD Million)
- Table 7 Global Pharmacogenomics Market for Polymerase Chain Reaction (PCR), by Country/Region, 2024-2036 (USD Million)
- Table 8 Global Pharmacogenomics Market for Sequencing, by Country/Region, 2024-2036 (USD Million)
- Table 9 Global Pharmacogenomics Market for Microarray, by Country/Region, 2024-2036 (USD Million)
- Table 10 Global Pharmacogenomics Market for Mass Spectrometry, by Country/Region, 2024-2036 (USD Million)
- Table 11 Global Pharmacogenomics Market for Electrophoresis, by Country/Region, 2024-2036 (USD Million)
- Table 12 Global Pharmacogenomics Market for Other Technologies, by Country/Region, 2024-2036 (USD Million)
- Table 13 Key Gene-drug Pairs, by Application
- Table 14 Global Pharmacogenomics Market, by Application, 2024-2036 (USD Million)
- Table 15 Global Pharmacogenomics Market for Oncology, by Country/Region, 2024-2036 (USD Million)
- Table 16 Global Pharmacogenomics Market for Mental Health, by Country/Region, 2024-2036 (USD Million)
- Table 17 Global Pharmacogenomics Market for Infectious Diseases, by Country/Region, 2024-2036 (USD Million)
- Table 18 Global Pharmacogenomics Market for Cardiology, by Country/Region, 2024-2036 (USD Million)
- Table 19 Global Pharmacogenomics Market for Neurological Disorders, by Country/Region, 2024-2036 (USD Million)
- Table 20 Global Pharmacogenomics Market for Pain Management, by Country/Region, 2024-2036 (USD Million)
- Table 21 Global Pharmacogenomics Market for Other Applications, by Country/Region, 2024-2036 (USD Million)
- Table 22 Global Pharmacogenomics Market, by End User, 2024-2036 (USD Million)
- Table 23 Routine Pharmacogenomic Testing in the NHS and U.S. Health Systems
- Table 24 Global Pharmacogenomics Market for Hospitals & Diagnostic Laboratories, by Country/Region, 2024-2036 (USD Million)
- Table 25 Global Pharmacogenomics Market for Academic & Research Institutes, by Country/Region, 2024-2036 (USD Million)
- Table 26 Global Pharmacogenomics Market for Pharmaceutical & Biotechnology Companies, by Country/Region, 2024-2036 (USD Million)
- Table 27 Global Pharmacogenomics Market for Other End Users, by Country/Region, 2024-2036 (USD Million)
- Table 28 Global Pharmacogenomics Market, by Region, 2024-2036 (USD Million)
- Table 29 North America: Pharmacogenomics Market, by Country/Region, 2024-2036 (USD Million)
- Table 30 North America: Pharmacogenomics Market, by Offering, 2024-2036 (USD Million)
- Table 31 North America: Pharmacogenomics Market, by Technology, 2024-2036 (USD Million)
- Table 32 North America: Pharmacogenomics Market, by Application, 2024-2036 (USD Million)
- Table 33 North America: Pharmacogenomics Market, by End User, 2024-2036 (USD Million)
- Table 34 U.S.: Pharmacogenomics Market, by Offering, 2024-2036 (USD Million)
- Table 35 U.S.: Pharmacogenomics Market, by Technology, 2024-2036 (USD Million)
- Table 36 U.S.: Pharmacogenomics Market, by Application, 2024-2036 (USD Million)
- Table 37 U.S.: Pharmacogenomics Market, by End User, 2024-2036 (USD Million)
- Table 38 Canada: Pharmacogenomics Market, by Offering, 2024-2036 (USD Million)
- Table 39 Canada: Pharmacogenomics Market, by Technology, 2024-2036 (USD Million)
- Table 40 Canada: Pharmacogenomics Market, by Application, 2024-2036 (USD Million)
- Table 41 Canada: Pharmacogenomics Market, by End User, 2024-2036 (USD Million)
- Table 42 Europe: National Approaches to Dpd Deficiency Testing
- Table 43 Europe: Pharmacogenomics Market, by Country/Region, 2024-2036 (USD Million)
- Table 44 Europe: Pharmacogenomics Market, by Offering, 2024-2036 (USD Million)
- Table 45 Europe: Pharmacogenomics Market, by Technology, 2024-2036 (USD Million)
- Table 46 Europe: Pharmacogenomics Market, by Application, 2024-2036 (USD Million)
- Table 47 Europe: Pharmacogenomics Market, by End User, 2024-2036 (USD Million)
- Table 48 Germany: Pharmacogenomics Market, by Offering, 2024-2036 (USD Million)
- Table 49 Germany: Pharmacogenomics Market, by Technology, 2024-2036 (USD Million)
- Table 50 Germany: Pharmacogenomics Market, by Application, 2024-2036 (USD Million)
- Table 51 Germany: Pharmacogenomics Market, by End User, 2024-2036 (USD Million)
- Table 52 France: Pharmacogenomics Market, by Offering, 2024-2036 (USD Million)
- Table 53 France: Pharmacogenomics Market, by Technology, 2024-2036 (USD Million)
- Table 54 France: Pharmacogenomics Market, by Application, 2024-2036 (USD Million)
- Table 55 France: Pharmacogenomics Market, by End User, 2024-2036 (USD Million)
- Table 56 U.K.: Pharmacogenomics Market, by Offering, 2024-2036 (USD Million)
- Table 57 U.K.: Pharmacogenomics Market, by Technology, 2024-2036 (USD Million)
- Table 58 U.K.: Pharmacogenomics Market, by Application, 2024-2036 (USD Million)
- Table 59 U.K.: Pharmacogenomics Market, by End User, 2024-2036 (USD Million)
- Table 60 Italy: Pharmacogenomics Market, by Offering, 2024-2036 (USD Million)
- Table 61 Italy: Pharmacogenomics Market, by Technology, 2024-2036 (USD Million)
- Table 62 Italy: Pharmacogenomics Market, by Application, 2024-2036 (USD Million)
- Table 63 Italy: Pharmacogenomics Market, by End User, 2024-2036 (USD Million)
- Table 64 Spain: Pharmacogenomics Market, by Offering, 2024-2036 (USD Million)
- Table 65 Spain: Pharmacogenomics Market, by Technology, 2024-2036 (USD Million)
- Table 66 Spain: Pharmacogenomics Market, by Application, 2024-2036 (USD Million)
- Table 67 Spain: Pharmacogenomics Market, by End User, 2024-2036 (USD Million)
- Table 68 Rest of Europe: Pharmacogenomics Market, by Offering, 2024-2036 (USD Million)
- Table 69 Rest of Europe: Pharmacogenomics Market, by Technology, 2024-2036 (USD Million)
- Table 70 Rest of Europe: Pharmacogenomics Market, by Application, 2024-2036 (USD Million)
- Table 71 Rest of Europe: Pharmacogenomics Market, by End User, 2024-2036 (USD Million)
- Table 72 Asia-Pacific: Pharmacogenomics Market, by Country/Region, 2024-2036 (USD Million)
- Table 73 Asia-Pacific: Pharmacogenomics Market, by Offering, 2024-2036 (USD Million)
- Table 74 Asia-Pacific: Pharmacogenomics Market, by Technology, 2024-2036 (USD Million)
- Table 75 Asia-Pacific: Pharmacogenomics Market, by Application, 2024-2036 (USD Million)
- Table 76 Asia-Pacific: Pharmacogenomics Market, by End User, 2024-2036 (USD Million)
- Table 77 China: Pharmacogenomics Market, by Offering, 2024-2036 (USD Million)
- Table 78 China: Pharmacogenomics Market, by Technology, 2024-2036 (USD Million)
- Table 79 China: Pharmacogenomics Market, by Application, 2024-2036 (USD Million)
- Table 80 China: Pharmacogenomics Market, by End User, 2024-2036 (USD Million)
- Table 81 Japan: Pharmacogenomics Market, by Offering, 2024-2036 (USD Million)
- Table 82 Japan: Pharmacogenomics Market, by Technology, 2024-2036 (USD Million)
- Table 83 Japan: Pharmacogenomics Market, by Application, 2024-2036 (USD Million)
- Table 84 Japan: Pharmacogenomics Market, by End User, 2024-2036 (USD Million)
- Table 85 India: Pharmacogenomics Market, by Offering, 2024-2036 (USD Million)
- Table 86 India: Pharmacogenomics Market, by Technology, 2024-2036 (USD Million)
- Table 87 India: Pharmacogenomics Market, by Application, 2024-2036 (USD Million)
- Table 88 India: Pharmacogenomics Market, by End User, 2024-2036 (USD Million)
- Table 89 South Korea: Pharmacogenomics Market, by Offering, 2024-2036 (USD Million)
- Table 90 South Korea: Pharmacogenomics Market, by Technology, 2024-2036 (USD Million)
- Table 91 South Korea: Pharmacogenomics Market, by Application, 2024-2036 (USD Million)
- Table 92 South Korea: Pharmacogenomics Market, by End User, 2024-2036 (USD Million)
- Table 93 Australia: Pharmacogenomics Market, by Offering, 2024-2036 (USD Million)
- Table 94 Australia: Pharmacogenomics Market, by Technology, 2024-2036 (USD Million)
- Table 95 Australia: Pharmacogenomics Market, by Application, 2024-2036 (USD Million)
- Table 96 Australia: Pharmacogenomics Market, by End User, 2024-2036 (USD Million)
- Table 97 Rest of Asia-Pacific: Pharmacogenomics Market, by Offering, 2024-2036 (USD Million)
- Table 98 Rest of Asia-Pacific: Pharmacogenomics Market, by Technology, 2024-2036 (USD Million)
- Table 99 Rest of Asia-Pacific: Pharmacogenomics Market, by Application, 2024-2036 (USD Million)
- Table 100 Rest of Asia-Pacific: Pharmacogenomics Market, by End User, 2024-2036 (USD Million)
- Table 101 Latin America: Pharmacogenomics Market, by Country/Region, 2024-2036 (USD Million)
- Table 102 Latin America: Pharmacogenomics Market, by Offering, 2024-2036 (USD Million)
- Table 103 Latin America: Pharmacogenomics Market, by Technology, 2024-2036 (USD Million)
- Table 104 Latin America: Pharmacogenomics Market, by Application, 2024-2036 (USD Million)
- Table 105 Latin America: Pharmacogenomics Market, by End User, 2024-2036 (USD Million)
- Table 106 Brazil: Pharmacogenomics Market, by Offering, 2024-2036 (USD Million)
- Table 107 Brazil: Pharmacogenomics Market, by Technology, 2024-2036 (USD Million)
- Table 108 Brazil: Pharmacogenomics Market, by Application, 2024-2036 (USD Million)
- Table 109 Brazil: Pharmacogenomics Market, by End User, 2024-2036 (USD Million)
- Table 110 Mexico: Pharmacogenomics Market, by Offering, 2024-2036 (USD Million)
- Table 111 Mexico: Pharmacogenomics Market, by Technology, 2024-2036 (USD Million)
- Table 112 Mexico: Pharmacogenomics Market, by Application, 2024-2036 (USD Million)
- Table 113 Mexico: Pharmacogenomics Market, by End User, 2024-2036 (USD Million)
- Table 114 Rest of Latin America: Pharmacogenomics Market, by Offering, 2024-2036 (USD Million)
- Table 115 Rest of Latin America: Pharmacogenomics Market, by Technology, 2024-2036 (USD Million)
- Table 116 Rest of Latin America: Pharmacogenomics Market, by Application, 2024-2036 (USD Million)
- Table 117 Rest of Latin America: Pharmacogenomics Market, by End User, 2024-2036 (USD Million)
- Table 118 Middle East & Africa: Pharmacogenomics Market, by Country/Region, 2024-2036 (USD Million)
- Table 119 Middle East & Africa: Pharmacogenomics Market, by Offering, 2024-2036 (USD Million)
- Table 120 Middle East & Africa: Pharmacogenomics Market, by Technology, 2024-2036 (USD Million)
- Table 121 Middle East & Africa: Pharmacogenomics Market, by Application, 2024-2036 (USD Million)
- Table 122 Middle East & Africa: Pharmacogenomics Market, by End User, 2024-2036 (USD Million)
- Table 123 Saudi Arabia: Pharmacogenomics Market, by Offering, 2024-2036 (USD Million)
- Table 124 Saudi Arabia: Pharmacogenomics Market, by Technology, 2024-2036 (USD Million)
- Table 125 Saudi Arabia: Pharmacogenomics Market, by Application, 2024-2036 (USD Million)
- Table 126 Saudi Arabia: Pharmacogenomics Market, by End User, 2024-2036 (USD Million)
- Table 127 UAE: Pharmacogenomics Market, by Offering, 2024-2036 (USD Million)
- Table 128 UAE: Pharmacogenomics Market, by Technology, 2024-2036 (USD Million)
- Table 129 UAE: Pharmacogenomics Market, by Application, 2024-2036 (USD Million)
- Table 130 UAE: Pharmacogenomics Market, by End User, 2024-2036 (USD Million)
- Table 131 Rest of Middle East & Africa: Pharmacogenomics Market, by Offering, 2024-2036 (USD Million)
- Table 132 Rest of Middle East & Africa: Pharmacogenomics Market, by Technology, 2024-2036 (USD Million)
- Table 133 Rest of Middle East & Africa: Pharmacogenomics Market, by Application, 2024-2036 (USD Million)
- Table 134 Rest of Middle East & Africa: Pharmacogenomics Market, by End User, 2024-2036 (USD Million)
- Table 135 Pharmacogenomics Market: Competitive Benchmarking, by Offering and Technology
- Table 136 Pharmacogenomics Market: Market Ranking, 2025
- Table 137 F. Hoffmann-La Roche Ltd: Product Portfolio
- Table 138 F. Hoffmann-La Roche Ltd: Strategic Developments, 2025-2026
- Table 139 Thermo Fisher Scientific Inc.: Product Portfolio
- Table 140 Thermo Fisher Scientific Inc.: Strategic Developments, 2025-2026
- Table 141 Illumina, Inc.: Product Portfolio
- Table 142 Illumina, Inc.: Strategic Developments, 2025-2026
- Table 143 Danaher Corporation: Product Portfolio
- Table 144 Danaher Corporation: Strategic Developments, 2025-2026
- Table 145 Agilent Technologies, Inc.: Product Portfolio
- Table 146 Agilent Technologies, Inc.: Strategic Developments, 2025-2026
- Table 147 QIAGEN N.V.: Product Portfolio
- Table 148 QIAGEN N.V.: Strategic Developments, 2025-2026
- Table 149 Abbott Laboratories: Product Portfolio
- Table 150 Abbott Laboratories: Strategic Developments, 2025-2026
- Table 151 Bio-Rad Laboratories, Inc.: Product Portfolio
- Table 152 Bio-Rad Laboratories, Inc.: Strategic Developments, 2025-2026
- Table 153 Revvity, Inc.: Product Portfolio
- Table 154 Revvity, Inc.: Strategic Developments, 2025-2026
- Table 155 Pacific Biosciences of California, Inc.: Product Portfolio
- Table 156 Pacific Biosciences of California, Inc.: Strategic Developments, 2025-2026
- Table 157 Myriad Genetics, Inc.: Product Portfolio
- Table 158 Myriad Genetics, Inc.: Strategic Developments, 2025-2026
LIST OF FIGURES
List of Figures
- Figure 1 Pharmacogenomics Market Ecosystem
- Figure 2 Research Process
- Figure 3 Primary Research Techniques
- Figure 4 Key Executives Interviewed
- Figure 5 Breakdown of Primary Interviews (Supply-Side & Demand-Side)
- Figure 6 Market Sizing and Growth Forecast Approach
- Figure 7 Global Pharmacogenomics Market Size, by Application, 2024-2036 (USD Million)
- Figure 8 Global Pharmacogenomics Market Size, 2024-2036 (USD Million)
- Figure 9 Global Pharmacogenomics Market, by Offering, 2026 vs. 2036 (USD Million)
- Figure 10 Global Pharmacogenomics Market, by Technology, 2026 vs. 2036 (USD Million)
- Figure 11 Global Pharmacogenomics Market, by Application, 2026 vs. 2036 (USD Million)
- Figure 12 Global Pharmacogenomics Market, by End User, 2026 vs. 2036 (USD Million)
- Figure 13 Pharmacogenomics Market, by Geography
- Figure 14 Factors Affecting Market Growth
- Figure 15 Share of New FDA Drug Approvals with Pharmacogenomic Labeling, by Therapeutic Area, 2000-2020 (%)
- Figure 16 Prepare Study: Clinically Relevant Adverse Drug Reactions in Patients with an Actionable Variant (%)
- Figure 17 Cost per CYP2C19 Test to Guide Clopidogrel After Stroke, by Testing Method (GBP)
- Figure 18 Porter's Five Forces Analysis
- Figure 19 Value Chain Analysis
- Figure 20 Global Pharmacogenomics Market, by Offering, 2026 vs. 2036 (USD Million)
- Figure 21 Leading Causes of Noncommunicable Disease Deaths Worldwide (Million Deaths per Year)
- Figure 22 Pacific Biosciences Revenue, by Category, 2025 (USD Million)
- Figure 23 Installed Base of Selected Sequencing Systems, End of 2025 (Units)
- Figure 24 Global Pharmacogenomics Market, by Technology, 2026 vs. 2036 (USD Million)
- Figure 25 NHS CYP2C19 Pilot: Stroke Patients Identified as Unlikely to Respond to Clopidogrel, by Testing Arm (%)
- Figure 26 Share of Patients with Actionable Pharmacogenomic Findings, by Study (%)
- Figure 27 Global Pharmacogenomics Market, by Application, 2026 vs. 2036 (USD Million)
- Figure 28 Hospitalization Among DPYD Variant Carriers, by Dosing Approach (%)
- Figure 29 Prime Care Trial: Prescribing and Remission Outcomes (%)
- Figure 30 Tailor-Pci Trial: Ischemic Events at 12 Months, All Randomized Patients (%)
- Figure 31 Global Pharmacogenomics Market, by End User, 2026 vs. 2036 (USD Million)
- Figure 32 Participants in Major Pharmacogenomic Studies
- Figure 33 Share of New FDA Drug Approvals with Pharmacogenomic Labeling, 2000 vs. 2020 (%)
- Figure 34 Pharmacogenomics Market, by Geography
- Figure 35 Global Pharmacogenomics Market, by Region, 2026 vs. 2036 (USD Million)
- Figure 36 North America: Pharmacogenomics Market Snapshot
- Figure 37 U.S.: Pharmacogenomics Market Size, 2024-2036 (USD Million)
- Figure 38 Canada: Pharmacogenomics Market Size, 2024-2036 (USD Million)
- Figure 39 Europe: Pharmacogenomics Market Snapshot
- Figure 40 Germany: Pharmacogenomics Market Size, 2024-2036 (USD Million)
- Figure 41 France: Pharmacogenomics Market Size, 2024-2036 (USD Million)
- Figure 42 U.K.: Pharmacogenomics Market Size, 2024-2036 (USD Million)
- Figure 43 Italy: Pharmacogenomics Market Size, 2024-2036 (USD Million)
- Figure 44 Spain: Pharmacogenomics Market Size, 2024-2036 (USD Million)
- Figure 45 Rest of Europe: Pharmacogenomics Market Size, 2024-2036 (USD Million)
- Figure 46 Carriers of CYP2C19 Loss-of-Function Alleles, by Ancestry (%)
- Figure 47 Asia-Pacific: Pharmacogenomics Market Snapshot
- Figure 48 China: Pharmacogenomics Market Size, 2024-2036 (USD Million)
- Figure 49 Japan: Pharmacogenomics Market Size, 2024-2036 (USD Million)
- Figure 50 India: Pharmacogenomics Market Size, 2024-2036 (USD Million)
- Figure 51 India: Price of a Basic Genomic Test, Current vs. Target (INR)
- Figure 52 South Korea: Pharmacogenomics Market Size, 2024-2036 (USD Million)
- Figure 53 Australia: Pharmacogenomics Market Size, 2024-2036 (USD Million)
- Figure 54 Rest of Asia-Pacific: Pharmacogenomics Market Size, 2024-2036 (USD Million)
- Figure 55 Latin America: Pharmacogenomics Market Snapshot
- Figure 56 Brazil: Pharmacogenomics Market Size, 2024-2036 (USD Million)
- Figure 57 Mexico: Pharmacogenomics Market Size, 2024-2036 (USD Million)
- Figure 58 Rest of Latin America: Pharmacogenomics Market Size, 2024-2036 (USD Million)
- Figure 59 Middle East and Africa: Pharmacogenomics Market Snapshot
- Figure 60 Saudi Arabia: Pharmacogenomics Market Size, 2024-2036 (USD Million)
- Figure 61 UAE: Pharmacogenomics Market Size, 2024-2036 (USD Million)
- Figure 62 Rest of Middle East & Africa: Pharmacogenomics Market Size, 2024-2036 (USD Million)
- Figure 63 Pharmacogenomics Market: Number of Strategic Developments, by Approach, January 2025-SEPTEMBER 2026
- Figure 64 Pharmacogenomics Market: Competitive Dashboard
- Figure 65 F. Hoffmann-La Roche Ltd: Financial Snapshot (2025)
- Figure 66 F. Hoffmann-La Roche Ltd: SWOT Analysis
- Figure 67 Thermo Fisher Scientific Inc.: Financial Snapshot (2025)
- Figure 68 Thermo Fisher Scientific Inc.: SWOT Analysis
- Figure 69 Illumina, Inc.: Financial Snapshot (2025)
- Figure 70 Illumina, Inc.: SWOT Analysis
- Figure 71 Danaher Corporation: Financial Snapshot (2025)
- Figure 72 Danaher Corporation: SWOT Analysis
- Figure 73 Agilent Technologies, Inc.: Financial Snapshot (2025)
- Figure 74 Agilent Technologies, Inc.: SWOT Analysis
- Figure 75 QIAGEN N.V.: Financial Snapshot (2025)
- Figure 76 QIAGEN N.V.: SWOT Analysis
- Figure 77 Abbott Laboratories: Financial Snapshot (2025)
- Figure 78 Abbott Laboratories: SWOT Analysis
- Figure 79 Bio-Rad Laboratories, Inc.: Financial Snapshot (2025)
- Figure 80 Bio-Rad Laboratories, Inc.: SWOT Analysis
- Figure 81 Revvity, Inc.: Financial Snapshot (2025)
- Figure 82 Revvity, Inc.: SWOT Analysis
- Figure 83 Pacific Biosciences of California, Inc.: Financial Overview
- Figure 84 Myriad Genetics, Inc.: Financial Snapshot (2025)
- Figure 85 Myriad Genetics, Inc.: SWOT Analysis
